Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 04/12/20 at 01:21pm

As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the world as global regulators race to review efficacy data without sacrificing robust analysis.

Our top ten most popular articles this week are unsurprisingly focused on many of the data and regulatory developments of these vaccine candidates.

10. EU fines Teva and Cephalon for keeping cheap sleep disorder medicine off the market

EU says the pair must pay $72 million for agreeing between themselves to delay the launch of Teva’s cheaper version of the Cephalon drug Modafinil.

9. FDA approves first drug to treat rare rapid ageing condition progeria

The FDA has approved the first drug to treat the rare genetic disorder progeria, a rare condition which causes cells to age rapidly and prematurely, leading children to appear older before they reach maturity

8. Japan approves Astellas and FibroGen's Evrenzo for chronic kidney disease patients currently not receiving dialysis

This is the pair’s second successful Japanese approval for the drug, which is already available in the country for the treatment of anaemia of CKD in adult patients on dialysis.

7. EMA receives Pfizer and BioNTech's filing for conditional approval of COVID-19 vaccine in Europe

Hopes are high for Pfizer and BioNTech’s vaccine after it recently demonstrated 95% efficacy in global Phase 3 trials, with this efficacy maintained in at-risk groups such as over-65s.

6. Grünenthal buys European rights to AstraZeneca's Crestor for a potential $350m

Upon closing of the deal expected in the first quarter of next year, Grünenthal will make an upfront payment of $320 million to AZ, with further milestone payments of up to $30 million to potentially follow.

5. AstraZeneca targeted by suspected North Korean hackers

Hackers suspected to be operating from North Korea have tried to break into the systems of AstraZeneca, two people with knowledge of the event told Reuters.

4. UK becomes first nation to approve Pfizer and BioNTech's COVID-19 vaccine

The vaccine is due to be rolled out via the NHS as early as next week, with an estimated 800,000 doses expected to be available. The UK has reserved 40 million doses in total from the drug’s makers.

3. Analysis confirms Moderna's COVID-19 vaccine efficacy to be 94.1%

On the back of the analysis, Moderna announced its intention to submit requests today with the FDA for Emergency Use Authorization, and for conditional approval from the EMA.

2. Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis

The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union to include the treatment of severe atopic dermatitis in paediatric patients between the age of six and 11 and are eligible to receive systemic therapy.

1. Drug-free nasal spray could prevent COVID-19 infection, promising data show

48 hours following initial treatment, average virus titers were shown to be 90% lower in reconstituted human nasal epithelia samples, compared to saline-treated control cultures in which the SARS-CoV-2 virus was shown to replicate effectively.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches